Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced the completion of its acquisition of MacroGenics, Inc.'s (NASDAQ: MGNX) GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for US $122.5 million. The transaction, closed through Bora's wholly owned subsidiary Bora Biologics USA, LLC, also includes a long-term CDMO Service Agreement with MacroGenics.
With this acquisition, Bora Biologics, the biologics CDMO franchise of Bora Group, now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites—Rockville, Maryland and San Diego, California—along with a development facility in Zhubei, Taiwan. This expansion establishes a US biologics manufacturing platform that supports sponsors from development through licensed commercial supply.
“This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply,” said Bobby Sheng, Chairman and CEO of Bora Group. “As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities.”
The Rockville facility adds to Bora Biologics' track record of supporting more than 4 active commercial programs and over 120 completed GMP batches, with supply into multiple global markets including the US, EU, Japan, Canada, and the UK, backed by fully integrated QC and analytical capabilities. Across its US network, Bora Biologics has completed five FDA inspections, including two at Rockville and one PMDA review in 2025, with clean results at both sites. The combined platform has supported more than 33 biologics and 15 biosimilars, providing a manufacturing base that reduces offshore dependency through domestically anchored infrastructure.
Bora Group plans to integrate its US drug substance capabilities with its existing sterile drug product capabilities over the next 12 to 18 months, aiming to offer a seamless, fully integrated development-through-commercial biologics solution. This move positions Bora as a comprehensive partner for biotech and pharmaceutical companies seeking reliable US-based manufacturing.
